Zoetis Inc. (ZTS)
Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy
Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO, outperforming the S&P 500. The company benefits from increasing global pet ownership and spending, making its revenues less susceptible to economic downturns. Zoetis boasts a strong competitive moat with a diverse product portfolio, significant patent protection, and consistent R&D investment.
Zoetis: The Major Player in the $500B Pet Market You May Not Have Heard Of
The pet industry is growing fast and could reach a global market size of half a trillion dollars by 2032. This episode looks at why people bought more pets during COVID, the trend of treating pets like family, and key public companies in the pet space, like Zoetis. Zoetis Executive Vice President and CFO Wetteny Joseph shares how the company works in both companion and production animal health. He talks about their top products, research investments, use of AI, and strong financial results. Despite challenges, Zoetis keeps pushing for innovation and profit in animal health.
1 Magnificent S&P 500 Dividend Stock Down 12% to Buy After Its Recent Pullback
Zoetis looks like a classic example of a premium business trading at a fair price following its recent dip.
Zoetis Q3: Strong Osteoarthritis Pain Franchise
I reiterate a 'Buy' rating for Zoetis with a one-year target price of $210 per share, driven by strong product performance and strategic divestitures. The Company's osteoarthritis drugs, LIBRELA and SOLENSIA, delivered 97% operational revenue growth, with LIBRELA poised to become a $1 billion franchise. Zoetis projects 10–11% operational revenue growth and 13.5–14.5% adjusted net income growth for FY24, despite minor headwinds from China.
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Brandon Vazquez - William Blair Jon Block - Stifel David Westenberg - Piper Sandler Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Chris LoBianco - TD Cowen Navann Ty - BNP Paribas Operator Welcome to the Third Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Zoetis raises full-year guidance on strong Q3 results
Zoetis Inc (NYSE:ZTS, ETR:ZOE) delivered another impressive quarter, with revenue and earnings exceeding Wall Street estimates for the third quarter of fiscal year 2024. For the period ended September 30, 2024, the animal health company reported revenues of $2.39 billion, marking an 11% increase year-over-year from $2.15 billion in Q3 2023, and surpassing analyst expectations of $2.29 billion.
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Zoetis Inc. For Fraud
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Compared to Estimates, Zoetis (ZTS) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zoetis raises annual forecasts on strong demand for pet treatments
Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.36 per share a year ago.
Zoetis Inc Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zoetis Inc. ("Zoetis" or "the Company") (NYSE:ZTS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
